-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-09-15
The reference study shows that intestinal, rather than solely hepatic, TM6SF2 deficiency can initiate MASH through altered fatty-acid handling, barrier failure, microbial dysbiosis and gut-derived lysophosphatidic acid. Its genetic, germ-free transplantation, co-housing and pharmacological experiments establish a mechanistic gut–liver axis and identify LPA-receptor signaling as a tractable intervention point.
-
Improving In Vitro Drug Response Evaluation in Cancer
2026-09-15
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response dimensions. This framework supports more interpretable assay design by encouraging researchers to measure response magnitude, mechanism, and timing separately rather than relying on a single viability endpoint.
-
Stable-Isotope UHPLC–MS/MS for Methylated Nucleosides
2026-09-14
Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS workflow for simultaneous measurement of 12 purine ribonucleosides, including 10 methylated species. Ammonium bicarbonate-enhanced ionization, chromatographic resolution of isomers, and methanol–SPE cleanup improved sensitivity for intracellular analysis and strengthened the analytical basis for RNA modification research and nucleoside biomarker discovery.
-
MACC1–HNRNPH1 Control of IRAK1 Splicing in LUAD
2026-09-14
The reference study identifies a direct connection between the oncogenic factor MACC1, the splicing regulator HNRNPH1, and IRAK1 isoform selection in lung adenocarcinoma. Its findings suggest that MACC1 promotes tumor-associated phenotypes by preserving the long IRAK1 isoform, providing a mechanistic framework for studying cancer-relevant alternative splicing.
-
Mitochondrial Pore Opening in Translational Research
2026-09-13
Mitochondrial permeability transition pore opening can connect mitochondrial dysfunction with cell-death decisions. This thought-leadership guide combines mechanistic interpretation, evidence from idiopathic carpal tunnel syndrome research, assay controls, and strategic guidance for using Calcein AM fluorescence in translational studies.
-
CARMIL MB Domain Regulates Actin Capping Protein
2026-09-12
A January 2026 preprint identifies the CARMIL membrane-binding domain as an active regulator rather than a passive membrane anchor. Its findings suggest that membrane attachment, CP recruitment, membrane release, uncapping, and Arp2/3-dependent actin assembly are coordinated through a dynamic MB–CP interaction.
-
Spermine Workflows for Ion Channel Research
2026-09-12
Spermine provides a biologically relevant way to probe inward rectifier potassium channel modulation, from voltage-controlled electrophysiology to carefully bounded membrane-fusion experiments. This workflow emphasizes concentration planning, solution handling, orthogonal controls, and clear separation between established channel biology and emerging CLCC1 research.
-
Thrombin B Chain Fragment in Fibrin Assays
2026-09-11
Use a sequence-defined human thrombin B chain fragment to separate peptide-associated effects from catalytic thrombin biology in fibrin, endothelial, platelet, and vascular workflows. This guide translates fibrin-matrix angiogenesis findings into practical assay controls, preparation parameters, and troubleshooting decisions.
-
(S)-(+)-Dimethindene maleate: Lab Guide
2026-09-11
This guide explains how to use (S)-(+)-Dimethindene maleate as a research tool for separating M2 muscarinic and H1 histamine receptor contributions in receptor and physiology assays. It is intended for controlled in vitro or ex vivo workflows, not for diagnostic, therapeutic, or medical use, and no directly matched paper evidence for SKU B6734 is assumed.
-
Sisomicin Workflows for Antibacterial Research
2026-09-10
Build more reliable Sisomicin assays by connecting 30S ribosome activity with paired extracellular, intracellular, and exposure-response measurements. This practical guide distinguishes product-backed conditions from hypothesis-generating workflow adaptations for Gram-negative and Gram-positive infection research.
-
MMP-2 Responsive Liposomes for Sequential Immunotherapy
2026-09-10
The reference study developed an MMP-2-responsive, dual-targeting liposome that sequentially delivers the PD-1 pathway blockade peptide AUNP-12 and the IDO inhibitor NLG919 in breast cancer models. Its main contribution is the use of tumor-associated protease activity to coordinate target-cell engagement, peptide release, secondary targeting, and immunosuppressive microenvironment remodeling.
-
gamma-Glu-Cys: From Substrate to Systems Insight
2026-09-09
Discover how gamma-Glu-Cys (γ-Glu-Cys) can function as more than a glutathione precursor: it is a controlled variable for enzyme assays, microbial peptide studies, and plant stress adaptation research. This guide connects molecular design, assay interpretation, and findings from recent Bacillus γ-glutamyl peptide research.
-
E. coli Uracil-DNA Glycosylase (UDG) Guide
2026-09-09
E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA to help control uracil-containing PCR carryover. It is intended for DNA workflows only and should not be used with RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-09-08
Wang et al. identify a METTL16–SENP3–LTF axis that links m6A RNA regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. The study integrates cellular, organoid, mouse-model, molecular, and clinical analyses, establishing labile iron control as a mechanistic connection between epitranscriptomic regulation and tumor progression.
-
2',7'-Dichlorofluorescein diacetate for ROS Assays
2026-09-08
Build more reliable intracellular ROS measurement workflows with a cell-permeable, fluorogenic redox probe that translates oxidative activity into green fluorescence. This guide connects practical assay design with the ROS-responsive nanocarrier strategy reported for orthotopic pancreatic cancer, while emphasizing controls, normalization, and interpretation limits.